PRAME and chronic myelogenous leukemia, BCR-ABL1 positive: PRAME hypomethylation might lead to its increased expression in CML blast crisis and AML, resulting in an enhancement of the oncogenic activity of PRAME.4, 5 Controversially, there are several reports showing that PRAME may be a tumour suppressor in haematological malignancies.